Iannaccone Alessandro

Yang Paul, Birch David, Lauer Andreas, Sisk Robert, Anand Rajiv, Pennesi Mark E et al.

Subretinal gene therapy (AGTC-501) for XLRP showed preliminary efficacy at a tolerated dose, but higher doses had concerning retinal side effects, guiding future treatment development.

Huryn Laryssa A, Kozycki Christina Torres, Serpen Jasmine Y, Zein Wadih M, Ullah Ehsan, Iannaccone Alessandro et al.

This study characterized ROSAH syndrome's ocular features, finding vision loss stems from optic nerve involvement, intraocular inflammation (e.g., CME), and progressive retinal degeneration, informing future treatment strategies.

Pennesi Mark Edward, Yang Paul, Birch David G, Weng Christina Y, Moore Anthony T, Iannaccone Alessandro et al.

This gene therapy for X-linked retinoschisis was generally safe but showed no measurable clinical benefit in vision, visual fields, or retinal structure, indicating limited efficacy for patients.

Birch David G, Samarakoon Lassana, Melia Michele, Duncan Jacque L, Ayala Allison R, Audo Isabelle et al.

Dark-adapted visual fields revealed rod function in most USH2A patients, even without measurable rod ERGs, suggesting DAVF may be a sensitive tool for monitoring rod-mediated disease progression.